Atomo Diagnostics (AT1) H2 2026 earnings summary

Executive summary

• Achieved 41% year-over-year revenue growth to AUD 5.3 million, driven by strong HIV and OEM sales, and a 39% improvement in EBITDA, moving closer to break-even.

• Cash receipts totaled AUD 10.2 million, with a year-end cash balance of AUD 3.7 million and no debt.

• Revenue streams diversified across HIV, OEM, and new product development, with strong cash generation from both sales and fundraising.

• Leadership transitioned to Dr. Cheri Walker as CEO, focusing on global commercial expansion.

• Expanded product pipeline with new tests for syphilis, liver function, and ferritin entering development.

Financial highlights

• Revenue increased 41% year-over-year to AUD 5.3 million, with HIV sales up 21% and OEM sales up 209%.

• Gross margin declined to 35% from 51% (or 42%), mainly due to the absence of prior year one-off license fees and a shift in sales mix toward lower-margin markets.

• Underlying EBITDA loss improved 39% to just over AUD 2 million (from AUD 3.38 million to AUD 2.06 million).

• Ended the period with AUD 3.7 million in cash and no debt, supported by AUD 4 million in capital raised.

• Total cash receipts were AUD 10.2 million, including AUD 4.6 million from customers and AUD 875k from R&D rebates.

Outlook and guidance

• Revenue growth expected to continue into FY27, supported by multiple growth engines and new product launches.

• Priorities include driving revenue growth, restoring margin strength, and maintaining cost discipline.

• Continued investment in product pipeline and operational improvements to support future launches and scale.

• Expansion of distribution channels and customer base anticipated, especially in HIV and OEM segments.

• Reinvestment in R&D and product development to drive future returns and broaden addressable markets.